SAB Biotherapeutics (SABS) Stock Chart & Stock Price History $2.69 +0.09 (+3.46%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SAB Biotherapeutics Stock Price Performance The SAB Biotherapeutics (SABS) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 2.54%, with a year-to-date return of -29.02%. In the past month, the stock has increased 51.12%, reflecting recent market activity. As of the latest close, SAB Biotherapeutics traded at $2.60 with a market cap of $24.15 million and volume of 548,075 shares. Receive SABS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+4.67%1 Month Performance+51.12%3 Month Performance+53.71%Year-To-Date Performance-29.02%1 Year Performance-2.54% SABS Stock Chart for Friday, July, 25, 2025 SABS Chart by TradingView SAB Biotherapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/24/2025$2.49$2.60+4.42%$2.85$2.43548,075 shs$24.15 million07/23/2025$2.61$2.49-4.60%$2.65$2.40608,599 shs$23.13 million07/22/2025$2.70$2.61-3.33%$2.69$2.241.42 million shs$24.25 million07/21/2025$2.57$2.70+5.06%$6.60$2.5981.62 million shs$25.08 million07/18/2025$2.84$2.57-9.51%$2.86$2.5711,307 shs$23.88 million07/17/2025$2.79$2.84+1.79%$2.89$2.6429,033 shs$26.38 million07/16/2025$2.54$2.79+9.84%$2.98$2.5937,041 shs$25.92 million07/15/2025$2.69$2.54-5.58%$2.84$2.3148,021 shs$23.59 million07/14/2025$2.60$2.69+3.46%$2.71$2.5855,370 shs$24.99 million07/11/2025$2.50$2.60+4.00%$2.73$2.4270,733 shs$24.15 million Get the Latest News and Ratings for SABS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/10/2025$2.55$2.50-1.96%$2.67$2.4449,441 shs$23.23 million07/09/2025$2.58$2.55-1.16%$2.72$2.4576,383 shs$23.69 million07/08/2025$1.96$2.58+31.63%$2.63$1.97188,081 shs$23.97 million07/07/2025$1.73$1.96+13.29%$2.10$1.7589,803 shs$18.21 million07/04/2025$1.73$1.73$1.82$1.7214,060 shs$16.07 million07/03/2025$1.75$1.73-1.14%$1.82$1.7214,060 shs$16.07 million07/02/2025$1.76$1.75-0.57%$1.79$1.735,713 shs$16.26 million07/01/2025$1.76$1.76+0.28%$1.78$1.703,107 shs$16.35 million06/30/2025$1.69$1.76+3.85%$1.79$1.6714,746 shs$16.30 million06/27/2025$1.78$1.69-5.06%$1.85$1.6918,811 shs$15.70 million06/26/2025$1.78$1.78$1.87$1.779,113 shs$16.54 million06/25/2025$1.80$1.78-1.11%$1.85$1.732,633 shs$16.53 million06/24/2025$1.76$1.80+2.27%$1.80$1.724,550 shs$16.72 million Related Companies ACHV Stock Chart DOMH Stock Chart FBIO Stock Chart CRIS Stock Chart BOLT Stock Chart MTEM Stock Chart AMGN Stock Chart GILD Stock Chart VRTX Stock Chart REGN Stock Chart Receive SABS Stock News and Ratings via EmailSign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SABS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SAB Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
